CASE PRESENTATION
A 75-year-old African American man was hospitalized at Baylor University Medical Center at Dallas in May 2012 after a recent fall and a 4-month history of progressive weakness. An evaluation by an oncologist 18 months earlier had disclosed a white cell count of 47,000 K/uL, hematocrit of 44%, and platelet count of 165,000 K/uL. A diff erential count at that time revealed many convoluted, atypical lymphocytes comprising 91% of the circulating mononuclear cells. Peripheral blood fl ow cytometry confi rmed a T-PLL with lymphocytes expressing CD2, CD3, CD4, CD5, CD7, CD26, and CD52. Th is population was negative for CD1a, CD8, and TdT. Th e clonal T-cell receptor beta gene rearrangement assays were positive. Cytogenetics confi rmed a complex karyotype including an inversion of chromosome 14 and isochromosomes 8q. Fluorescence in situ hybridization also revealed 11q22 deletion and 17p13 loss. Th e patient was lost to follow up, and he did not return for marrow assessment or to discuss treatment options.
On this admission, he was lethargic and appeared chronically ill. Medications included amlodipine, rosuvastatin, and ranitidine. Th ere was no peripheral lymphadenopathy. Auscultation of the chest revealed diff use rhonchi, normal heart sounds, and a 2/6 systolic murmur. His spleen was palpable 7.0 cm below the costal margin. His hematocrit was 29% and his white blood cell count was 476,000 K/uL with 96% lymphocytes and 3% neutrophils. Many atypical large lymphocytes with slightly convoluted nuclei containing prominent nucleoli and copious nongranular cytoplasm were present (Figure 1a) . Th e platelet count was 47,000 K/uL. Blood cultures on admission were positive for coagulase-negative Staphylococcus. Uric acid was 7.9 mg/ dL, and lactate dehydrogenase was markedly elevated at 2369 u/L (reference range 185-249). Creatinine was 1.6 mg/dL, and liver function studies were normal. A computed tomography scan of the chest revealed mediastinal lymphadenopathy, and an abdominal sonogram confi rmed the splenomegaly.
On the second hospital day, a bone marrow biopsy ( Figure 1b ) along with fl ow cytometry and cytogenetics confi rmed T-PLL. During his hospitalization he was treated with a 7-day course of 2-chlorodeoxyadenosine at 0.1 mg/kg intravenously daily by continuous infusion. He was maintained on broad-spectrum antibiotics but developed renal insuffi ciency and recurrent gastrointestinal bleeding secondary to a benign esophageal ulcer documented on endoscopy. His white blood cell count only marginally improved with his chemotherapy, with a white count of 199,000 K/uL after 6 days of chemotherapy. At that time intensive care was withheld, comfort care measures were instituted, and the patient died on the 10th hospital day.
DISCUSSION
T-PLL, a rare hematological malignancy, was fi rst described in 1973. It represents <2% of mature lymphocytic leukemias (1, 6, 7). T-PLL primarily aff ects older adults with an average age at presentation of 65 years with a slight male predominance (8) . Most patients present with hepatosplenomegaly (splenomegaly in 82% to 92%) and generalized lymphadenopathy (1). Other common fi ndings include skin lesions (27%) and pleural serous eff usions (14%) (7) .
The peripheral blood commonly exhibits anemia and thrombocytopenia with a marked lymphocytosis and lymphocyte counts frequently >100,000 K/uL (7). A distinctive hematologic aspect is a rapidly rising white blood cell count with a doubling time of weeks to months (9) . Th e key morphologic feature in the diagnosis of T-PLL is a population of prolymphocytes in the peripheral blood. Th e typical morphology consists of prolymphocytes of medium size with condensed nuclear chromatin, a single prominent nucleolus, and intensely basophilic nongranular cytoplasm with cytoplasmic protrusions or "blebs." Th e nuclei can be round, oval, or irregular (10, 11) . In 25% of cases, the cell size is smaller and the nucleolus may not be visible by light microscopy (small cell variant) (12) . In 5% the nuclear outline is markedly irregular and can even be cerebriform, mimicking Sézary cells (13) . Both of these variants are otherwise similar to typical T-PLL, including immunophenotype and cytogenetics, and thus it is justifi ed that all three are grouped together in a single category (11) .
Th e bone marrow is diff usely infi ltrated by prolymphocytes in most cases with variable residual hematopoiesis. Reticulin fi brosis is almost always present (10, 11) . When the spleen is involved, histology fi nds a dense red pulp infi ltrate with invasion into the splenic capsule, blood vessels, and extension into the atrophied white pulp. In lymph nodes, the involvement is diff use with paracortical expansion by T prolymphocytes, sometimes with sparing of follicles (14) . Multiple prominent highendothelial venules are often infi ltrated by neoplastic cells (10) . Skin involvement diff ers from that seen in mycosis fungoides and Sézary syndrome, with dermal infi ltrates primarily around the appendages and without epidermotropism (7, 15) .
Immunophenotypically, T prolymphocytes are mature postthymic peripheral T cells that do not express TdT and the cortical thymic marker CD1a. Th e cells are positive for CD2, CD3, and CD5 and have strong CD7 staining. Th is strong CD7 intensity is in contrast to other mature T-cell malignancies, where this marker may be weak or negative. Th e membrane expression of CD3 may be weak or even negative in occasional cases, but T-cell receptor-beta/gamma chain genes are always rearranged. CD52 is usually expressed at high density in T prolymphocytes and can be used as a target of therapy by the monoclonal antibody alemtuzumab (8, 16) . In 65% of patients, the cells are CD4 + , CD8 -, and in 13% they are CD4 -, CD8 + . In 21% the T prolymphocytes coexpress CD4 and CD8, which is a feature almost unique to T-PLL. Th e distinctive coexpression of CD4 and CD8 together with the weak CD3 membrane expression and the strong CD7 expression suggest that the T-PLL cell may be at an intermediate stage of diff erentiation between a cortical thymocyte and a circulating mature T cell (7) . Th e most specifi c markers for T-PLL by immunophenotyping are CD26 and TCL-1 protein expression, which are not detected in the other mature T-cell leukemia/ lymphomas (11) . Th e overexpression of the oncogene TCL1 is useful for detecting residual T-PLL in bone marrow sections after therapy (9) .
T-PLL is characterized by complex chromosomal abnormalities, which suggests that chromosomal aberrations might occur progressively during the course of the disease, thus explaining the aggressive nature of this condition. Recurrent changes mainly aff ect chromosomes 14, 8, 11, and X (17) . Th e most common characteristic chromosome abnormality, seen in 80% of cases, is inversion of chromosome 14 with breakpoints in the long arm at q11 and q32 (inv (14)(q11;q32) ). Reciprocal tandem translocations between the two chromosomes 14 occur in 10% (t14;14)(q11;q32) (17, 18) . Th ese two rearrangements involve the 14q11 and 14q32.1 loci, where the genes coding for TCRα and the protooncogene TCL-1 are localized, respectively. Th e rearrangements result in juxtaposition of these two genes and lead to expression and activation of TCL-1 (19) . About 20% of patients have the translocation t(X;14)(q28;q11), which results in rearrangement of the MTCP1 gene (20) . Both TCL-1 and MTCP-1 have oncogenic properties, as both can induce a T-cell leukemia (CD4 -/CD8 + ) in transgenic mice (19, 21, 22) . Abnormalities involving both arms of chromosome 8 are frequent, t(8;8)(p11-12;q12) as well as trisomy 8q, with both being seen in 70% to 80% of cases. Other alterations seen in T-PLL include deletions of 12p13 and 11q22, with the latter being the locus for the ataxia telangiectasia mutated gene. Abnormalities of chromosome 6 and 17 and deletion of the TP53 gene are also not uncommonly encountered (10) .
T-PLL is aggressive and often resistant to therapy. Th e overall prognosis is poor, with a median survival of approximately 7 months in patients treated with conventional regimens. Recently the average survival has been extended to >2 years following the introduction of newer therapies (11) . Th e initial treatment of choice for most patients is the monoclonal antibody alemtuzumab (anti-CD52); the best responses have been seen with this agent, but responses are still transient and further disease progression is inevitable (3, 23) . Purine analogues also have activity in this disease (24, 25) . Both autologous and allogeneic stem cell transplants in patients who achieve remission have been used and are associated with more durable outcomes (26) . Because of the severe immunosuppression associated with alemtuzumab, the purine analogue 2-chlorodeoxyadenosine was selected for the reported patient's treatment.
